Press Releases

NEW YORK, June 4, 2024 /PRNewswire/ -- As temperatures rise and Father's Day approaches, finding the perfect gift that appreciates Dad while keeping him comfortable during summer can be challenging. Recognizing this need, the modern men's essentials designer brand COOFANDY is thrilled to introduce a series of garments that blend style with comfort. The collection features pieces made from premium fabrics that are breathable, lightweight, and skin-friendly – ideal... (continue reading...)

Bilbao, Spain, Brazil 4 June 2024.- Virtualware (EPA: MLVIR), the European leader in virtual reality, has signed a partnership agreement with Axxist to boost VIROO's presence in Latin America.

The Guatemala City-based company specializes in delivering disruptive technology solutions focused on digital transformation and Industry 4.0 in Latin America and the United States.

As a VIROO Value Added Reseller, Axxist will promote the adoption of the enterprise virtual... (continue reading...)

HYDERABAD, India, June 4, 2024 /PRNewswire/ -- AmpleLogic, a leading provider of GAMP solutions, announces the launch of its revolutionary Application Platform as a Service (aPaaS) designed specifically for the life sciences sector. This cutting-edge platform leverages low-code/no-code technology to accelerate digitization in life sciences industry while enhancing operational efficiency and ensuring compliance with regulatory standards from USFDA, MHRA, EMEA, ISO, and... (continue reading...)

• Successful completion of several long production cycles to deliver the first commercial volumes of acids
• Confirmation of the objective to start continuous production in 2024

CLERMONT-FERRAND, France & LYON, France--(BUSINESS WIRE)-- Regulatory News:

AFYREN (Paris:ALAFY), a greentech company that offers manufacturers bio-based, low-carbon ingredients produced using unique fermentation technology based on a completely circular model, provided an update on... (continue reading...)

PARIS--(BUSINESS WIRE)-- Regulatory News:

GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its participation at key medical and stakeholder meetings in the remainder of 2024.

On June 4, three papers on LUMEVOQ®, the company’s gene therapy for Leber... (continue reading...)